Your browser doesn't support javascript.
loading
Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development.
Hays, Amanda; Wissel, Mark; Colletti, Kelly; Soon, Russell; Azadeh, Mitra; Smith, Justin; Doddareddy, Rajitha; Chalfant, Melanie; Adamowicz, Wendy; Ramaswamy, Swarna Suba; Dholakiya, Sanjay L; Guelman, Sebastian; Gullick, Bryan; Durham, Jennifer; Rennier, Keith; Nagilla, Pruthvi; Muruganandham, Anamica; Diaz, Manisha; Tierney, Cassandra; John, Kaarthik; Valentine, Jenny; Lockman, Timothy; Liu, Hsing-Yin; Moritz, Benjamin; Ouedraogo, Jean Paul; Piche, Marie-Soleil; Smet, Muriel; Murphy, Jacqueline; Koenig, Kaylyn; Zybura, Agnes; Vyhlidal, Carrie; Mercier, Jonathan; Jani, Niketa; Kubista, Mikael; Birch, Donald; Morse, Karlin; Johansson, Oskar.
Afiliação
  • Hays A; BioAgilytix Laboratories, Durham, North Carolina, USA. amanda.hays@bioagilytix.com.
  • Wissel M; Eurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA.
  • Colletti K; Beam Therapeutics, Cambridge, Massachusetts, USA.
  • Soon R; BioMarin Pharmaceutical Inc., Novato, California, USA.
  • Azadeh M; Ultragenyx Pharmaceutical Inc., Novato, Calfornia, USA.
  • Smith J; Pfizer Inc, Groton, Connecticut, USA.
  • Doddareddy R; Merck & Co., Inc., Rahway, New Jersey, USA.
  • Chalfant M; GSK, Collegeville, Pennsylvania, USA.
  • Adamowicz W; PPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA.
  • Ramaswamy SS; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Dholakiya SL; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Guelman S; Genentech, Inc., South San Francisco, California, USA.
  • Gullick B; BioAgilytix Laboratories, Durham, North Carolina, USA.
  • Durham J; BioAgilytix Laboratories, Boston, Massachusetts, USA.
  • Rennier K; Labcorp Drug Development, Greenfield, Indiana, USA.
  • Nagilla P; Asher Biotherapeutics, Inc., South San Francisco, California, USA.
  • Muruganandham A; BioAgilytix Laboratories, Durham, North Carolina, USA.
  • Diaz M; Eurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA.
  • Tierney C; Pfizer Inc, Groton, Connecticut, USA.
  • John K; REGENXBIO Inc., Rockville, Maryland, USA.
  • Valentine J; Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • Lockman T; PPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA.
  • Liu HY; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Moritz B; Charles River Labs, Reno, Nevada, USA.
  • Ouedraogo JP; Charles River Labs, Senneville, Québec, Canada.
  • Piche MS; Charles River Labs, Senneville, Québec, Canada.
  • Smet M; Sanofi, Ghent, Belgium.
  • Murphy J; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Koenig K; Altasciences Preclinical Seattle LLC, Everett, Washington, USA.
  • Zybura A; Labcorp Drug Development, Greenfield, Indiana, USA.
  • Vyhlidal C; KCAS Bioanalytical and Biomarker Services, Shawnee, Kansas, USA.
  • Mercier J; Flowmetric Life Sciences, Inc., Spring House, Pennsylvania, USA.
  • Jani N; BioAgilytix Laboratories, Boston, Massachusetts, USA.
  • Kubista M; Institute of Biotechnology Czech Academy of Sciences, Prague, Czech Republic.
  • Birch D; Altasciences Preclinical Seattle LLC, Everett, Washington, USA.
  • Morse K; Altasciences Preclinical Seattle LLC, Everett, Washington, USA.
  • Johansson O; TATAA Biocenter, Gothenburg, Sweden.
AAPS J ; 26(1): 24, 2024 02 05.
Article em En | MEDLINE | ID: mdl-38316745
ABSTRACT
The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Desenvolvimento de Medicamentos Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Desenvolvimento de Medicamentos Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
...